Bioterrorism Watch: CE/CME Questions
Objectives
After reading each issue of Bioterrorism Watch, the infection control professional will be able to do the following:
• identify the particular clinical, legal or educational issue related to bioterrorism;
• describe how the issue affects health care providers, hospitals, or the health care industry in general;
• cite solutions to the problems associated with bioterrorism, based on guidelines from the federal Centers for Disease Control and Prevention or other authorities, and/or based on independent recommendations from clinicians and bioterrorism experts.
CE/CME Questions
Please save your bimonthly issues with the CE questions in order to take the two semester tests in the May/June and November/December issues. A Scantron sheet will be inserted in those issues, but the questions will not be repeated.
1. Some medical consultants and advisors cautioned about a host of potential side effects from smallpox vaccine, which could be particularly hazardous to the 300,000 people in the United States who do not know they have:
A. hepatitis C virus
B. tuberculosis
C. HIV
D. variola
2. William Bicknell, MD, PhD, argued that which group of people are much less likely than first-time smallpox vaccinees to have any adverse reaction:
A. dairy workers
B. those who have been previously vaccinated for smallpox
C. those already immunized with other live vaccines
D. all of the above
3. Progressive vaccinia, a potentially fatal complication of smallpox vaccination, has occurred almost exclusively among:
A. immunocompromised people
B. women
C. those infected in sub-Sahara Africa during the 1960s
D. those vaccinated under poor sanitary conditions
4. The American Hospital Association stated that the Centers for Disease Control and Prevention’s smallpox response plan could substantially increase confusion or promote misinformation at a time when implementation of standard procedures would be critical.
A. true
B. false
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.